Clinical Research Directory
Browse clinical research sites, groups, and studies.
Application of the CD73-Targeted Probe ⁶⁸Ga-DOTA-mPNE PET/CT Imaging in the Diagnosis of Malignant Tumors
Sponsor: Peking Union Medical College Hospital
Summary
This study aims to perform ⁶⁸Ga-DOTA-mPNE PET/CT imaging in patients with clinically suspected or confirmed malignant tumors, in order to evaluate tracer uptake in lesions and analyze CD73 expression levels. In a subgroup of up to 10 participants, dynamic PET/CT imaging will be conducted for up to 90 minutes post-injection to assess the tracer's biodistribution and pharmacokinetic properties.Correlation analyses with relevant clinical indicators (such as pathology, immunohistochemistry, and molecular markers) will be carried out to further assess the diagnostic performance and clinical value of ⁶⁸Ga-DOTA-mPNE PET/CT in guiding tumor diagnosis and treatment. This study is expected to provide a novel molecular imaging tool for malignancies and offer clear, intuitive PET/CT-based evidence to support clinical diagnosis, differential diagnosis, and therapeutic decision-making.
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2025-07-10
Completion Date
2026-06-17
Last Updated
2025-08-05
Healthy Volunteers
Yes
Conditions
Interventions
68Ga-DOTA-mPNE
PET/CT examination was performed after intravenous injection of 68GA-DOTA-mPNE tracer
Locations (1)
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China